Latest Ovarian Cancer News

Page 1 of 7
Cleo Diagnostics has commissioned three Ella immunoassay instruments at a US laboratory as it prepares to begin the final major clinical testing program for its pre-surgical ovarian cancer test. The approximately 1,470-sample program is intended to support a planned FDA 510(k) submission in the first half of calendar 2027, but no clinical results have yet been reported.
Ada Torres
Ada Torres
12 Nov 2026
INOVIQ has secured a validation agreement with Sonic Healthcare USA for its EXO-OC ovarian cancer test, opening a potential route into the US laboratory-developed test market. The commercial opportunity remains conditional: Sonic has not committed to a licence, and validation is expected to run for 12 to 18 months.
Ada Torres
Ada Torres
2 Nov 2026
INOVIQ will restart its EXO-OC ovarian cancer program through a staged optimisation and verification process after an independent review found sample collection and handling were the main sources of variability. The company is targeting US laboratory-developed test readiness in the first half of 2028, while a leadership change adds another moving part.
Ada Torres
Ada Torres
29 Oct 2026
Amplia Therapeutics is preparing the next stage of narmafotinib’s pancreatic cancer development as its ACCENT trial nears completion and a Lilly collaboration broadens the drug’s potential into lung cancer. The biotech ended September with $20.8 million in cash, rising to $25.6 million pro forma after an October R&D tax refund.
Victor Sage
Victor Sage
28 Oct 2026
Amplia Therapeutics has received an A$4.78 million refundable R&D tax rebate, giving the clinical-stage biotechnology company additional cash to advance its FAK inhibitor programs. The funds will support multiple narmafotinib trials and related research, including studies involving Lilly.
Victor Sage
Victor Sage
22 Oct 2026
Cleo Diagnostics’ prototype ovarian cancer screening test met or exceeded every predefined performance target in a 247-person proof-of-concept study, including among 62 Stage I cases. The result moves the program into larger bridging and expanded studies, but it remains retrospective evidence rather than a validated screening test.
Ada Torres
Ada Torres
21 Oct 2026
Cleo Diagnostics has moved its pre-surgical ovarian cancer test into formal Analytical Validation, a key regulatory step before its planned FDA 510(k) submission in the first half of 2027. The three-batch program is expected to take about three months, but no validation results have yet been reported.
Victor Sage
Victor Sage
13 Oct 2026
Cleo Diagnostics has begun developing a multi-biomarker blood test for ovarian cancer screening in asymptomatic women, targeting a stated $150 billion global market. The prototype program will run alongside the company’s pre-surgical test, with initial proof-of-concept data expected early next quarter.
Victor Sage
Victor Sage
24 Sept 2026
Imagion Biosystems has signed nanoComposix to resume GMP-aligned manufacturing of the MagSense nanoparticle core, a move designed to support its FDA-cleared HER2 breast cancer programme without the fixed cost of an in-house facility. The agreement improves manufacturing readiness, but its value, duration and production commitments remain undisclosed.
Victor Sage
Victor Sage
14 Sept 2026
Cleo Diagnostics has appointed Bio-Techne’s CLIA-certified U.S. laboratory Asuragen to run pivotal clinical validation for its pre-surgical ovarian cancer test. The approximately 1,470-sample program is intended to generate the evidence supporting a planned FDA 510(k) submission in the first half of calendar 2027.
Ada Torres
Ada Torres
10 Sept 2026
Cleo Diagnostics has received its first commercial batch of ovarian cancer test kits from Bio-Techne, marking the start of analytical validation critical for its FDA submission planned in early 2027.
Ada Torres
Ada Torres
3 Sept 2026
Imagion Biosystems has signed key CRO work orders and completed manufacturing of its MagSense HER2 Imaging Agent, advancing its Phase 1b/2 clinical trial targeting HER2+ breast cancer. Trial initiation is underway with seven prospective sites, including contract talks with the first US clinical site.
Ada Torres
Ada Torres
26 Aug 2026

Browse the archive

Full archive